These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

600 related items for PubMed ID: 17768706

  • 1. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
    Jeon YK, Park CH, Kim KY, Li YC, Kim J, Kim YA, Paik JH, Park BK, Kim CW, Kim YN.
    J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
    [Abstract] [Full Text] [Related]

  • 2. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.
    Georgakis GV, Li Y, Younes A.
    Br J Haematol; 2006 Oct; 135(1):68-71. PubMed ID: 16925576
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A.
    Clin Cancer Res; 2006 Jan 15; 12(2):584-90. PubMed ID: 16428504
    [Abstract] [Full Text] [Related]

  • 4. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
    Yu W, Rao Q, Wang M, Tian Z, Lin D, Liu X, Wang J.
    Leuk Res; 2006 May 15; 30(5):575-82. PubMed ID: 16213582
    [Abstract] [Full Text] [Related]

  • 5. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T, Ohyashiki K.
    Cancer Lett; 2009 Oct 18; 284(1):62-70. PubMed ID: 19464103
    [Abstract] [Full Text] [Related]

  • 6. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
    Schumacher JA, Crockett DK, Elenitoba-Johnson KS, Lim MS.
    Proteomics; 2007 Aug 18; 7(15):2603-16. PubMed ID: 17610208
    [Abstract] [Full Text] [Related]

  • 7. Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells.
    Wu WC, Wu MH, Chang YC, Hsieh MC, Wu HJ, Cheng KC, Lai YH, Kao YH.
    Exp Eye Res; 2010 Aug 18; 91(2):211-9. PubMed ID: 20493187
    [Abstract] [Full Text] [Related]

  • 8. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.
    Nimmanapalli R, O'Bryan E, Bhalla K.
    Cancer Res; 2001 Mar 01; 61(5):1799-804. PubMed ID: 11280726
    [Abstract] [Full Text] [Related]

  • 9. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
    Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, Grant S.
    Cancer Res; 2003 Dec 01; 63(23):8420-7. PubMed ID: 14679005
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 11. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
    Johnson AJ, Wagner AJ, Cheney CM, Smith LL, Lucas DM, Guster SK, Grever MR, Lin TS, Byrd JC.
    Br J Haematol; 2007 Dec 01; 139(5):837-44. PubMed ID: 17949452
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection.
    Demidenko ZN, Vivo C, Halicka HD, Li CJ, Bhalla K, Broude EV, Blagosklonny MV.
    Cell Death Differ; 2006 Sep 01; 13(9):1434-41. PubMed ID: 16311509
    [Abstract] [Full Text] [Related]

  • 13. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Blaser BW, Freud AG, Chou J, Chen CS, Xiao JJ, Parthun M, Chan KK, Eisenbeis CF, Ferketich AK, Grever MR, Chen CS, Caligiuri MA.
    J Natl Cancer Inst; 2004 Oct 06; 96(19):1447-57. PubMed ID: 15467034
    [Abstract] [Full Text] [Related]

  • 14. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.
    Clin Cancer Res; 2006 Nov 15; 12(22):6826-35. PubMed ID: 17121904
    [Abstract] [Full Text] [Related]

  • 15. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo.
    Lesko E, Gozdzik J, Kijowski J, Jenner B, Wiecha O, Majka M.
    Anticancer Drugs; 2007 Nov 15; 18(10):1173-81. PubMed ID: 17893518
    [Abstract] [Full Text] [Related]

  • 16. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2008 Jun 15; 49(6):2348-56. PubMed ID: 18281615
    [Abstract] [Full Text] [Related]

  • 17. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling.
    Ng SB, Selvarajan V, Huang G, Zhou J, Feldman AL, Law M, Kwong YL, Shimizu N, Kagami Y, Aozasa K, Salto-Tellez M, Chng WJ.
    J Pathol; 2011 Mar 15; 223(4):496-510. PubMed ID: 21294123
    [Abstract] [Full Text] [Related]

  • 18. [Study on signal transduction pathway in differentiation and apoptosis of leukemia cells induced by heat shock protein inhibitor].
    Yu WJ, Rao Q, Wang M, Tian Z, Xu ZF, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct 15; 28(10):677-80. PubMed ID: 18399173
    [Abstract] [Full Text] [Related]

  • 19. High anti tumor activity against rhabdomyosarcoma cells and low normal cells cytotoxicity of heat shock protein 90 inhibitors, with special emphasis on 17-[2-(pyrrolidin-1-yl)ethyl]-aminno-17-demethoxygeldanamycin.
    Lukasiewicz E, Miekus K, Kijowski J, Gozdzik J, Wilusz M, Bobis-Wozowicz S, Wiecha O, Majka M.
    J Physiol Pharmacol; 2009 Sep 15; 60(3):161-6. PubMed ID: 19826195
    [Abstract] [Full Text] [Related]

  • 20. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
    Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S, Kumaraswamy S, Balasis M, Greedy B, Armitage ES, Lawrence N, Bhalla K.
    Cancer Res; 2005 Nov 15; 65(22):10536-44. PubMed ID: 16288046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.